Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)

2015311 citationsJournal Articlegreen Open Access

Authors

Deirdre R. Pachman · Pfizer (United States)

Rui Qin · Eli Lilly (United States)

Drew K. Seisler · Cancer Center of Kansas

Elizabeth Smith · Eli Lilly (United States)

Andreas S. Beutler · Bristol-Myers Squibb (Germany)

Lauren E. Ta · Boston Biomedical (United States)

Jacqueline M. Lafky

Abstract

Acute oxaliplatin-induced neuropathy symptoms do not always completely resolve between treatment cycles and are only half as severe on the first cycle as compared with subsequent cycles. There is a correlation between the severities of acute and chronic neuropathies.

Topics & Keywords

Cancer Treatment and Pharmacology Chemotherapy-related skin toxicity Multiple Myeloma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 33, Issue 30, pp. 3416-3422

DOI: 10.1200/jco.2014.58.8533

Field-Weighted Citation Impact: 8.33